GET DAILY SIGNALSDiversified Healthcare Trust (DHC) Delivers Stronger Operating Results but Lowers 2026 Normalized FFO Outlook
Key Takeaways
- Diversified Healthcare Trust reported third-quarter 2026 normalized FFO of $0.13 per share, below the consensus estimate of $0.15.
- Revenue came in at $367.67 million, down 5.4% year over year and slightly below the consensus expectation of $370.87 million.
- The company's net loss narrowed to $50.2 million ($0.21 per share) from $164 million ($0.68 per share) a year earlier.
- Same-property SHOP NOI rose 50.4% year over year, supported by a 200-basis-point occupancy gain and 5.2% rate growth.
- Management lowered full-year 2026 normalized FFO guidance to $110.7 million–$125.7 million from $135 million–$150 million, while raising same-property SHOP NOI guidance to $190 million–$200 million.
- DHC maintained its quarterly cash distribution of $0.01 per common share.
- You can find more information about DHC's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Explore Trending AI Robots to see AI-driven trading strategies in action.
Earnings Context and Why It Matters
Diversified Healthcare Trust is a REIT focused on senior housing, medical office, and life science properties across the United States. Its results provide insight into the ongoing turnaround in its senior living portfolio, which represents the largest portion of its roughly $6.3 billion asset base. After multiple quarters of net losses, attention has centered on occupancy trends, rate growth, and cost management. The latest quarter combined solid same-property performance with a downward revision to full-year normalized FFO guidance, underscoring both the momentum and the remaining cost challenges.
Reported Results
For the quarter ended September 30, 2026, DHC posted normalized FFO of $0.13 per share, missing the $0.15 consensus by $0.02. Revenue totaled $367.67 million, a 5.4% decline from the prior-year quarter and just below the $370.87 million estimate.
The net loss improved to $50.2 million, or $0.21 per share, from $164 million ($0.68 per share) in the year-ago period. This narrower loss reflects higher operating income and reduced expenses tied to the recovery efforts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Operating metrics stood out positively. Same-property SHOP NOI increased 50.4% year over year, driven by a 200-basis-point occupancy rise and 5.2% growth in average monthly resident rates. The company also leased 130,000 square feet of medical office space at rents 25.2% above prior levels, with a weighted average lease term of 9.7 years.
Guidance was adjusted downward for normalized FFO to $110.7 million–$125.7 million from the prior $135 million–$150 million range, and adjusted EBITDAre was lowered to $275.7 million–$290.7 million from $300 million–$315 million. At the same time, same-property SHOP NOI guidance was raised to $190 million–$200 million from $185 million–$195 million.
Market Reaction and Investor Sentiment
The results paint a mixed picture. The year-over-year gains in same-property SHOP NOI, occupancy, and resident rates indicate the senior housing recovery is advancing. Yet the reduction in full-year normalized FFO and adjusted EBITDAre guidance suggests one-time benefits and higher seasonal utility costs affected sequential profitability, with expense and capital pressures still present. The modest misses versus consensus, alongside the guidance reset, are likely to moderate near-term sentiment even as underlying trends improve.
Forward Outlook and Key Factors to Monitor
Looking ahead, focus should remain on the sustainability of the senior housing recovery. The raised same-property SHOP NOI guidance for 2026 points to continued momentum in occupancy and rates, the key drivers for the largest segment. At the same time, the lowered normalized FFO and adjusted EBITDAre ranges highlight offsetting factors such as seasonal utility costs, the absence of one-time benefits, and ongoing capital expenditures for community refreshes. Additional leasing progress in medical office assets and any portfolio transactions could also affect the balance sheet and future earnings. The upcoming conference call should offer further clarity on expense trends and how occupancy and rate growth are expected to flow through to results for the rest of 2026 and into 2027. From what I see, these elements will shape performance in the quarters ahead.
Using Tickeron’s AI Tools in My Research
I often turn to Tickeron’s AI Screener when evaluating REITs like this one. It lets me quickly filter for stocks with similar fundamentals, technical patterns, and performance metrics, helping me build a more informed watchlist without spending hours on manual screening. The tool has become a regular part of how I cross-check operating trends and compare names across the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DHC in downward trend: price dove below 50-day moving average on November 02, 2026
DHC moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend. In 33 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for DHC moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
DHC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DHC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DHC's RSI Indicator exited the oversold zone, 21 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DHC as a result. In 68 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for DHC just turned positive on October 20, 2026. Looking at past instances where DHC's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
The 10-day moving average for DHC crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +2.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHC advanced for three days, in 218 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 30 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.184) is normal, around the industry mean (3.125). P/E Ratio (-6.973) is within average values for comparable stocks, (28.561). Projected Growth (PEG Ratio) (0.910) is also within normal values, averaging (1.649). DHC has a moderately low Dividend Yield (0.005) as compared to the industry average of (0.049). DHC's P/S Ratio (1.274) is slightly lower than the industry average of (6.013).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers.
Industry PublishingBooksMagazines
Advertisement